Xudong Qu

Dr. Xudong Qu

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
PWPeng‐Xiang Wang
Peng‐Xiang Wang
YSYun‐Fan Sun
Yun‐Fan Sun
KZKai‐Qian Zhou
Kai‐Qian Zhou
JCJian‐Wen Cheng
Jian‐Wen Cheng
BHBo Hu
Bo Hu
XYXin-Rong Yang
Xin-Rong Yang
Background: High rates of postoperative tumor recurrence contribute to poor outcome in hepatocellular carcinoma (HCC). Here, we investigated whether circulating tumor cells (CTCs) status can predict the benefit of adjuvant transcatheter arterial chemoembolization (TACE) in patients with HCC.Methods: The retrospective study enrolled 344 HCC patients with preoperative CTCs analysis. Clinical outcomes including recurrence and survival were compared between those who received and who did not receive adjuvant TACE. Similar comparisons were made for patients stratified according to CTC status (CTC‐negative [CTC = 0], n = 123; CTC‐positive [CTC ≥ 1], n = 221). Propensity score matching (PSM) strategy was adopted to offset differences between two groups.Results: In the study cohort as a whole or in CTC‐negative cohort, there were no observable differences in overall survival (OS) or time to recurrence (TTR) between TACE and control group (P > .05). In CTC‐positive patients, PSM generated 64 patient pairs, and patients with adjuvant TACE had significantly better clinical outcomes (OS: not reached vs 36.4 months, P < .001; TTR: 45.8 vs 9.8 months, P < .001). Adjuvant TACE significantly reduced early recurrence (≤2 years) (64.1% vs 31.7%, P < .001) in CTC‐positive patients. Notably, adjuvant TACE influenced TTR and OS even in subgroups of CTC‐positive patients with low risk of recurrence according to traditional evaluation.Conclusions: Preoperative CTC status could serve as an indicator for the administration of adjuvant TACE in HCC patients. Adjuvant TACE benefits CTC‐positive HCC patients mainly by reducing early recurrence.


2 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
JWJuncheng Mbbs Wan
Juncheng Mbbs Wan
BTBufu Tang
Bufu Tang
WZWen Zhang
Wen Zhang
YZYongjie Zhou
Yongjie Zhou
CJChaoqiao Mbbs Jin
Chaoqiao Mbbs Jin
XQXudong Qu
Xudong Qu
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Emerging evidence suggests that quadruple therapy – combining hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), targeted therapy, and immunotherapy – improves outcomes. However, few studies have directly compared this regimen with triple therapy (TACE plus targeted therapy and immunotherapy), and the optimal sequence of locoregional treatments within this regimen remains unclear. Objective: To compare the efficacy and safety of HAIC-first quadruple therapy, TACE-first quadruple therapy, and triple therapy in patients with unresectable HCC (uHCC). Materials and Methods: We retrospectively analyzed 158 patients with uHCC who received: HAIC-first quadruple therapy (HTTI, n = 61), TACE-first quadruple therapy (THTI, n = 41), or triple therapy (TTI, n = 56). Tumor response was assessed with modified RECIST; progression-free survival (PFS), overall survival (OS), and safety were compared. Results: The HTTI group achieved the highest objective response rate (ORR, 81.97%) and disease control rate (DCR, 96.72%), outperforming the THTI (ORR 73.17%, DCR 95.12%) and TTI groups (ORR 64.28%, DCR 85.71%). The median OS (mOS) was not reached in the HTTI group; the THTI group had a longer mOS (22.30 months) than the TTI group (19.00 months, P = 0.046). The median PFS (mPFS) was also longer in the HTTI group (12.90 months), compared to the THTI (10.40 months, P = 0.042) group and TTI groups (9.30 months, P < 0.001). Quadruple therapy increased grade 1 and 2 hypoalbuminemia, thrombocytopenia, and hand-foot syndrome, but grade 3 and 4 toxicities were similar across groups. Conclusion: Quadruple therapy demonstrates superior efficacy compared to triple therapy for uHCC. Initiating treatment with HAIC followed by TACE appears more effective than the reverse sequence and merits prospective validation.

19 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
ZZZi-Han Zhang
Zi-Han Zhang
SHSi-Nan Hou
Si-Nan Hou
JYJia-Ze Yu
Jia-Ze Yu
WZWen Zhang
Wen Zhang
JMJing-Qin Ma
Jing-Qin Ma
ZYZhiping Yan
Zhiping Yan
Objective: To evaluate the safety and efficacy of interventional therapy (iodine-125[125I] seed strand and portal vein stent [PVS] implantation plus transarterial chemoembolization [TACE]) combined with systemic therapy (lenvatinib plus anti-PD-1 antibody) as first-line treatment for hepatocellular carcinoma (HCC) patients with Vp4 portal vein tumor thrombus (PVTT).Patients and methods: From December 2018 to October 2021, 87 HCC patients with Vp4 PVTT were included in this single-center retrospective study. Forty-seven patients underwent interventional therapy combined with lenvatinib and anti-PD-1 antibody (group A), while 40 cases underwent interventional therapy combined with lenvatinib only (group B). Overall response rate (ORR), stent occlusion rates (SOR), median overall survival (OS), median progression-free survival (PFS) and median stent patency time (SPT) were compared between the 2 groups.Results: The mean intended dose (r = 10 mm; z = 0; 240 days) was 64.9 ± 1.0 Gy and 64.5 ± 1.1 Gy in group A and B, respectively (p = 0.133). ORR and SOR were significantly different between group A and B (ORR, 55.3% vs 17.5%, p < 0.001; SOR, 12.8% vs 35.0%, p = 0.014). In the propensity-score matching (PSM) cohort, the median OS, median PFS and median SPT were significantly longer in group A compared with group B (32 PSM pairs; OS, 17.7 ± 1.7 vs 12.0 ± 0.8 months, p = 0.010; PFS, 17.0 ± 4.3 vs 8.0 ± 0.7 months, p < 0.001; SPT, not-reached vs 12.5 ± 1.1 months, p = 0.028).Conclusion: This interventional therapy combined with lenvatinib and anti-PD-1 antibody is safe and effective for HCC patients with Vp4 PVTT.

17 September 2025 in Liver International
Verified
Journal Article
Open access
YZYanting Zou
Yanting Zou
Szu-Yuan WuSzu-Yuan Wu
Szu-Yuan Wu
WZWanqin Zhang
Wanqin Zhang
WZWei Zhang
Wei Zhang
XSXizhong Shen
Xizhong Shen
QYQunyan Yao
Qunyan Yao
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality. Transarterial chemoembolization (TACE) is the standard locoregional therapy for unresectable HCC but is limited by high recurrence and hepatic toxicity. Low‐molecular‐weight fucoidan (LMF), a sulfated polysaccharide from brown seaweed, has anticancer and hepatoprotective properties. This study assessed whether LMF enhances tumour response and preserves liver function when combined with TACE. Methods: In this randomised, double‐blind, placebo‐controlled trial, 82 patients with unresectable HCC were randomly assigned (1:1) to receive LMF (4.4 g twice daily) or placebo for 6 months in addition to TACE. Tumour response was assessed using modified RECIST criteria, and liver function was monitored via Child–Pugh classification. The primary endpoint was disease control rate (DCR), with objective response rate (ORR), liver function and adverse events as secondary endpoints. Results: Baseline characteristics were well balanced. DCR was significantly higher in the LMF group (95.24% vs. 80.00%, p = 0.035), with a lower progressive disease rate (4.76% vs. 20.00%). ORR was higher in the LMF group (52.38% vs. 35.00%) but not statistically significant ( p = 0.1129). LMF preserved liver function ( p = 0.029), with more patients maintaining Child–Pugh Class A (80.95% vs. 62.50%). Adverse event rates were similar, and no severe adverse events occurred. Conclusions: LMF improved tumour control, preserved liver function and had a favourable safety profile. These findings suggest LMF may mitigate TACE‐related hepatic toxicity and prolong treatment eligibility, warranting further validation in larger trials.

2 May 2013 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
WZWen Zhang
Wen Zhang
ZYZhiping Yan
Zhiping Yan
JLJianjun Luo
Jianjun Luo
ZFZhu-ting Fang
Zhu-ting Fang
LWLinlin Wu
Linlin Wu
JWJianhua Wang
Jianhua Wang